Charles Schwab Investment Management Inc. Acquires 40,386 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Charles Schwab Investment Management Inc. lifted its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 4.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 996,748 shares of the company's stock after purchasing an additional 40,386 shares during the period. Charles Schwab Investment Management Inc. owned 0.80% of Apellis Pharmaceuticals worth $31,806,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Braidwell LP lifted its position in shares of Apellis Pharmaceuticals by 410.8% in the third quarter. Braidwell LP now owns 3,125,183 shares of the company's stock worth $90,130,000 after buying an additional 2,513,383 shares during the last quarter. Jennison Associates LLC lifted its holdings in Apellis Pharmaceuticals by 51.6% in the 4th quarter. Jennison Associates LLC now owns 2,760,404 shares of the company's stock worth $88,084,000 after purchasing an additional 939,289 shares during the last quarter. JPMorgan Chase & Co. boosted its position in Apellis Pharmaceuticals by 23.3% during the third quarter. JPMorgan Chase & Co. now owns 3,884,730 shares of the company's stock worth $112,036,000 after purchasing an additional 735,160 shares during the period. Sphera Funds Management LTD. acquired a new position in Apellis Pharmaceuticals during the third quarter valued at approximately $6,226,000. Finally, Ieq Capital LLC raised its position in shares of Apellis Pharmaceuticals by 1,425.5% in the fourth quarter. Ieq Capital LLC now owns 126,710 shares of the company's stock valued at $4,043,000 after purchasing an additional 118,404 shares during the period. 96.29% of the stock is currently owned by institutional investors.

Remove Ads

Insider Buying and Selling

In other Apellis Pharmaceuticals news, CEO Cedric Francois sold 6,247 shares of the company's stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $28.70, for a total transaction of $179,288.90. Following the sale, the chief executive officer now directly owns 307,415 shares of the company's stock, valued at approximately $8,822,810.50. This represents a 1.99 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Caroline Baumal sold 2,816 shares of the firm's stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $33.81, for a total transaction of $95,208.96. Following the sale, the insider now directly owns 55,560 shares of the company's stock, valued at approximately $1,878,483.60. The trade was a 4.82 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 66,117 shares of company stock worth $1,954,803 in the last 90 days. 6.80% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on APLS shares. Royal Bank of Canada decreased their price objective on shares of Apellis Pharmaceuticals from $26.00 to $25.00 and set a "sector perform" rating for the company in a report on Monday, March 3rd. Wedbush lowered their price target on Apellis Pharmaceuticals from $30.00 to $29.00 and set a "neutral" rating on the stock in a research report on Monday, March 3rd. HC Wainwright reiterated a "buy" rating and issued a $57.00 price objective on shares of Apellis Pharmaceuticals in a research note on Monday, March 3rd. JPMorgan Chase & Co. increased their target price on Apellis Pharmaceuticals from $50.00 to $54.00 and gave the company an "overweight" rating in a research note on Tuesday, March 4th. Finally, Morgan Stanley assumed coverage on Apellis Pharmaceuticals in a report on Thursday, November 21st. They issued an "equal weight" rating and a $31.00 target price on the stock. Eight investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $45.53.

Apellis Pharmaceuticals Price Performance

Shares of NASDAQ:APLS traded down $0.65 during midday trading on Thursday, reaching $24.16. 793,329 shares of the company's stock were exchanged, compared to its average volume of 1,927,708. The company has a debt-to-equity ratio of 1.91, a quick ratio of 3.73 and a current ratio of 4.36. The company's 50 day simple moving average is $27.78 and its two-hundred day simple moving average is $30.27. Apellis Pharmaceuticals, Inc. has a 12 month low of $23.77 and a 12 month high of $59.91. The firm has a market capitalization of $3.03 billion, a PE ratio of -11.94 and a beta of 0.92.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last announced its quarterly earnings results on Friday, February 28th. The company reported ($0.29) EPS for the quarter, topping analysts' consensus estimates of ($0.37) by $0.08. The firm had revenue of $212.50 million during the quarter, compared to analysts' expectations of $197.92 million. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The company's revenue for the quarter was up 45.2% compared to the same quarter last year. During the same quarter last year, the company earned ($0.73) earnings per share. Equities research analysts expect that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).